Last updated on April 2019

Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)


Brief description of study

Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research.

Adults might be able to join this study after bone marrow tests show they have a certain kind of blood cancer (FLT3-ITD AML).

Participants will have an equal chance of receiving quizartinib or placebo along with their chemotherapy.

Detailed Study Description

This is a phase 3, randomized, double-blind, placebo-control global study. The purpose of this study is to compare the effect of quizartinib versus placebo (administered with standard induction and consolidation chemotherapy, then administered as continuation therapy for up to 36 cycles) on event-free survival in subjects with FLT3-internal tandem duplication (ITD) positive AML.

Clinical Study Identifier: NCT02668653

Find a site near you

Start Over

Ronald Reagan UCLA Medical Center

Los Angeles, CA United States
  Connect »

Cleveland Clinic Foundation

Cleveland, OH United States
  Connect »

Flinders Medical Centre

Bedford Park, Australia
  Connect »

Queen Mary Hospital

Hong Kong, Hong Kong
  Connect »

Box Hill Hospital

Box Hill, Australia
  Connect »

Sanatorio Allende

Córdoba, Argentina
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.